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Collismycin A is a member of the 2,20-bipyridyl family
of natural products that shows cytotoxic activity.
Structurally, it belongs to the hybrid polyketides-
nonribosomal peptides. After the isolation and
characterization of the collismycin A gene cluster,
we have used the combination of two different ap-
proaches (insertional inactivation and biocatalysis)
to increase structural diversity in this natural product
class. Twelve collismycin analogs were generated
with modifications in the second pyridine ring of
collismycin A, thus potentially maintaining biologic
activity. None of these analogs showed better cyto-
toxic activity than the parental collismycin. However,
some analogs showed neuroprotective activity and
one of them (collismycin H) showed better values
for neuroprotection against oxidative stress in a
zebrafishmodel than those of collismycin A. Interest-
ingly, this analog also showed very poor cytotoxic
activity, a feature very desirable for a neuroprotec-
tant compound.
INTRODUCTION
Microorganisms are an important source of bioactive natural
products. About half of them are produced by members of the
actinomycetes family (Be´rdy, 2005; Butler, 2008; Demain and
Sanchez, 2009; Newman and Cragg, 2007; Olano et al., 2011).
One of the most important groups of bioactive compounds is
hybrid polyketides-nonribosomal peptides. They contain both
polyketide and peptide moieties and therefore multifunctional
enzymes with assembly line-like structures and are responsible
for the biosynthesis of these hybrid compounds (Du and Shen,
2001). In these compounds, usually the polyketide moiety is syn-
thesized by a type I compound (modular polyketide synthase).
Collismycin A (Figure 1A) is a member of the 2,20-bipyridyl
family of natural products that also includes SF2738B-F (Gomi
et al., 1994), pyrisulfoxins (Tsuge et al., 1999), and caerulomycins1022 Chemistry & Biology 20, 1022–1032, August 22, 2013 ª2013 El(Funk and Divekar, 1959; McInnes et al., 1977, 1978). Overall,
several biologic activities have been associated with members
of this family of natural products such as antibacterial, antifungal,
and cytotoxic activities (Gomi et al., 1994; Stadler et al., 2001)
and they also have potential as anti-inflammatory agents through
binding to the glucocorticoid receptor (Shindo et al., 1994) or
as neuroprotectants by reducing oxidative stress in neurons
(Martinez et al., 2007). Using labeled precursors, lysine-derived
picolinic acid (PA) has been proposed to be a precursor for the
biosynthesis of these compounds (McInnes et al., 1979; Vining
et al., 1988). Based on their chemical structures, it can be pre-
dicted that they must be synthesized by a hybrid polyketide syn-
thetase-nonribosomal peptide synthetase (PKS-NRPS) system.
This was confirmed through the isolation and characterization
of the collismycin A gene cluster from Streptomyces sp. CS40
(Garcia et al., 2012) and, more recently, with the caerulomycin
gene cluster from Actinoalloteichus cyanogriseus (Qu et al.,
2012; Zhu et al., 2012). With the availability of the sequence of
the collismycin A gene cluster, we were interested in under-
standing how collismycin A biosynthesis takes place and in
generating collismycin analogs with potentially improved thera-
peutic properties. We report a detailed characterization of late
steps in collismycin A biosynthesis. Gene replacement mutants
were generated in seven genes of the cluster, seven analogs
were isolated, and their structures elucidated. In addition, five
other analogs were also produced by biocatalysis. Overall, a pic-
ture on how collismycin biosynthesis takes place has emerged.
We tested the biologic activity of the 12 analogs as cytotoxic
agents, but none of them improved the activity of the parental
compound. However, several analogs showed neuroprotective
activity against oxidative stress when tested in a zebrafish
model, and one of them improved the level of neuroprotection
above that of collismycin A.
RESULTS
Insertional Inactivation of Genes Involved in Late
Biosynthesis Steps: Generation of Analogs with
Modifications in the Substituted Pyridine Ring
Three phases have been proposed in the biosynthesis of collis-
mycin A (Garcia et al., 2012): (1) biosynthesis and activation ofsevier Ltd All rights reserved
Figure 1. Collismycin A
(A) Structure of collismycin A.
(B) Genetic organization of the collismycin A gene
cluster. Gene replacement mutants were gener-
ated in the genes indicated in gray.
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Generation of Collismycin AnalogsPA from L-lysine; (2) formation of the 2,20-bypiridyl, and
(3) tailoring modifications of the 2,20-bipyridyl structure. The
deduced products of several genes of the cluster could be
involved in the third phase of the biosynthesis: clmG1, clmG2,
clmAT, clmD1, clmD2, clmM, and clmM2 (Figure 1B) and would
catalyze enzymatic reactions taking place once the 2,20-bypiridyl
structure has been formed.
The pair of genes, clmG1 and clmG2, shows high similarity
with griC and griD from Streptomyces griseus, genes known to
catalyze a carboxylic acid reduction in grixazone biosynthesis
(Suzuki et al., 2007). During the third phase of collismycin A
biosynthesis, the formation of an intermediate carrying a carbox-
ylic group has been proposed (Garcia et al., 2012) and this inter-
mediate could be a good substrate for ClmG1/ClmG2, reducing
the carboxylic group to an aldehyde. Because clmG1 and clmG2
are supposed to act together in collismycin biosynthesis, we
generated a mutant lacking both genes by gene replacement.
Mutant CLM-G1G2 did not produce collismycin A but instead
accumulated a compound (Figure 2) with a mass of 263 m/z
[M+H]. Structural elucidation of the compound revealed a
2,20-bipyridyl family member differing from collismycin A in
possessing a carboxyl group in position 6 and a hydroxyl group
in position 4. We designated this compound collismycin C
(Figure 3). To verify if collismycin C was a real intermediate or a
shunt product, the nonproducing mutant CLM-N1, blocked in
the NRPS gene clmN1 (Garcia et al., 2012), was fed with collis-
mycin C. The mutant was able to convert collismycin C into
collismycin A, suggesting that collismycin C is a real intermediate
(Figure 4A).
The products of genes clmM1 and clmAH were postulated to
act first after the 2,20-bipyridyl ring formation (Garcia et al., 2012).
To confirm this, the previously isolated collismycin SC, a com-
pound accumulated by the CLM-AH mutant (Garcia et al.,
2012), was fed to the CLM-G1G2 mutant. It was found that the
latter mutant was unable to generate collismycin A from collis-
mycin SC. However, almost all collismycin SC was converted
into collismycin C (Figure 4B). These results support a role for
ClmAH as an amidohydrolase, as suggested previously (Garcia
et al., 2012), with collismycin C as the product of the reaction.
The gene clmAT appears to encode a putative aminotrans-
ferase showing high identity with diaminobutyrate-pyruvate
aminotransferases (above 50% identity and above 70% similar-
ity) and with BatP (28% identity and 47% similarity), an amino-
transferase involved in kalimantacin/batumin-related polyketide
biosynthesis in Pseudomonas fluorescens (Mattheus et al.,Chemistry & Biology 20, 1022–1032, August 22, 20132010). These enzymes catalyze the trans-
amination reaction from a donor, usually
an amino acid, to an aldehyde group pre-
sent in the acceptor molecule. ClmAT is
supposed to introduce the nonpyridylic
nitrogen of collismycin A via transamina-tion. Gene clmAT was inactivated by gene replacement and
the resulting mutant CLM-AT was found not to produce any of
the previously known collismycins, but instead accumulates
two compounds (Figure 2) with masses of 249 and 263 m/z
[M+H]+, respectively. Both compoundswere purified, their struc-
tures elucidated with nuclear magnetic resonance (NMR), and
found to contain a hydroxymethyl group in position 6 but differ
in that the heavier compound contains a methoxy group in posi-
tion 4, while the lighter compound contains a hydroxyl group in
that position. These compounds were designated as collismycin
H and collismycin DH, respectively (Figure 3). Both compounds
were also independently fed to cultures of mutant CLM-N1 to
determine if they were real intermediates (Figures 4C and 4D)
or shunt products. The mutant converted collismycin DH into
collismycins A and H; however, when fed with collismycin H,
no reaction was observed. The presence of a hydroxymethyl
group instead of the expected aldehyde group in position 6 of
collismycins H and DH can be explained by the reactivity of
the aldehyde group, which in the hypoxic cytosolic environment
might be reduced spontaneously to a hydroxymethyl group.
Genes clmD1 and clmD2 of the cluster encode putative dehy-
drogenases that could be involved in oxidative processes during
late steps of collismycin A biosynthesis. The predicted protein
sequence of ClmD1 shows high homology with acyl-CoA dehy-
drogenases from various organisms. The predicted sequence
contains an acyl-CoA dehydrogenase domain typically found in
FAD-dependent oxidases that reduce CoA-bound substrates
(Kim and Battaile, 2002). Inactivation of clmD1 by gene replace-
ment rendered a mutant (CLM-D1 mutant) unable to produce
collismycin A or any related compound (Figure 2). This mutant
can convert collismycin C or collismycin DH into collismycin A
and also produces minor amounts of collismycin H in both cases
(as well as collismycin DH when fed with collismycin C; Figures
4F and 4G). In addition, this mutant can convert collismycin SN
(a compound accumulated by a methyltransferase-minus
mutant, CLM-M1; Garcia et al., 2012). These results suggest
that the reaction catalyzed by ClmD1 occurs early in the biosyn-
thetic pathway, before collismycin SN is formed.
Gene clmD2 encodes a putative FAD-dependent dehydroge-
nase, and the deduced ClmD2 protein shows high similarity with
TamL, a protein involved in oxidative tailoring modifications dur-
ing tirandamycin biosynthesis (Carlson et al., 2010). Although we
have no specific role assigned to ClmD2, the enzyme likely par-
takes in the oxime formation, i.e., late in collismycin biosynthesis.
Inactivation of clmD2 by gene replacement generated mutantª2013 Elsevier Ltd All rights reserved 1023
Figure 2. UPLC Analyses of Cultures of Mutants in Different Genes of the Collismycin A Gene Cluster
Mutants were grown for 7 days at 30C in R5A liquid medium. Cultures were then extracted with either ethyl acetate (wild-type and CLM-AT, CLM-D2-, and CLM-
M2 mutants) or ethyl acetate containing 10% formic acid (CLM-M and CLM-G1G2 mutants). After solvent evaporation, the extracts were analyzed by UPLC. All
chromatograms were extracted at 330 nm with the exception of that of CLM-G1G2 mutant, which was extracted at 280 nm.
Chemistry & Biology
Generation of Collismycin AnalogsCLM-D2, which still produces collismycin A but also accumu-
lates collismycins H and DH (Figure 2). Production of collismycin
A by the CLM-D2mutant and the fact that collismycin DH can be
converted into collismycin A by mutant CLM-N1 (Figure 4C) sug-
gests that ClmD2 might be responsible for oxidizing the hydrox-
ymethyl group in position 5 of collismycin DH to an aldehyde
group, which is the most likely substrate for the aminotrans-
ferase reaction catalyzed by ClmAT. Such an oxidative reaction
would confer ClmD2 the function of recovering the spontane-
ously generated shunt product collismycin DH for the main
pathway. However, we cannot exclude that another dehydroge-
nase present in the cell—although less efficiently—may be able
to catalyze this recovery-reaction.
The clmM gene product shows high similarity with putative
FAD-dependent oxidoreductases and monooxygenases (Garcia
et al., 2012). Because no monooxygenase has been found
to participate in the 2,20-bipirydine formation (Qu et al., 2012),
ClmM could be necessary for late steps of the collismycin forma-
tion, possibly catalyzing the oxime group formation. Upon inac-
tivation of the clmM gene, the resulting mutant CLM-M did not
produce collismycin A, but accumulated a compound (Figure 2)
with a mass of m/z 290 [M+H]+. Structural elucidation of this
compound revealed that it contains a hydroxyl group in position
4 and an N-methylacetamide group in position 6, and was desig-1024 Chemistry & Biology 20, 1022–1032, August 22, 2013 ª2013 Elnated as collismycin DA (Figure 3). Feeding experiments using
mutant CLM-N1 showed that collismycin DA was not further
modified (Figure 4H), suggesting collismycin DA to be a shunt
product of the pathway, probably generated by acetylation of a
real intermediate by an acetyltransferase present in the microor-
ganism, a common enzyme to detoxify exposed amino groups.
Finally, the gene product of clmM2 is very similar to AzicL, an
O-methyltransferase involved in azicemicin biosynthesis (Oga-
sawara and Liu, 2009). ClmM2 has been proposed to generate
the methoxy group of collismycin A (Garcia et al., 2012). Upon
clmM2 inactivation through gene replacement, the resulting
mutant CLM-M2 did not produce collismycin A, but did accumu-
late three analogs (Figure 2) with masses of m/z 278, 262, and
244 [M+H]+, which were designated as collismycins DS, D, and
DN, respectively. Structure elucidation of these compounds
resulted in the identification of three 2,20-bipyridyl ring-contain-
ing molecules with a hydroxyl group in position 4 (Figure 3). Col-
lismycin D and collismycin DN (and also collismycin A) contain a
methylthio substituent in position 5, while collismycin DS con-
tains a methylsulfinyl substituent in that position. However, the
main difference between themwas at position 6, where collismy-
cin D (as well as collismycin A) contains an aldoxime group, while
collismycin DN contains a cyano group in that position, probably
resulting from dehydration of the aldoxime. Nitrile groups havesevier Ltd All rights reserved
Figure 3. Structures of Collismycin Analogs Generated in This Work
See also Figures S1–S26.
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Generation of Collismycin Analogsbeen reported forming part of the structure of natural products
(Fleming, 1999; Bezerra Gomes et al., 2010) and a route for the
formation of this nitrile group has been proposed (Olano et al.,
2004). Collismycin DS contains an amido group in position 6,
which could have resulted from a (spontaneous?) hydration of
the cyano group. This type of substituent has also been reported
for other natural products (Bezerra Gomes et al., 2010). Feeding
experiments were carried out with these compounds, again
using the early block mutant CLM-N1, to determine if any of
these were biosynthetic intermediates. (1) Collismycin D was
converted into collismycin A by the mutant (Figure 4I), and a
significant amount of collismycin H was also detected in thisChemistry & Biology 20, 1022–bioconversion experiment. (2) The CLM-N1 mutant was also
able to modify collismycin DS, to produce small amounts of an
undetermined compound (indicated by an asterisk in Figure 4J),
which was not purified. However, high-performance liquid chro-
matography/mass spectroscopy (HPLC/MS) findings suggest
the presence of a methoxy group at position 4. (3) The CLM-
N1 mutant was unable to modify collismycin DN (Figure 4K).
Generation of Acylated Analogs of Collismycin H by
Biocatalysis
Collismycin H (Figure 3) was the major compound accumu-
lated by CLM-AT mutant. The primary hydroxyl group of this1032, August 22, 2013 ª2013 Elsevier Ltd All rights reserved 1025
(legend on next page)
Chemistry & Biology
Generation of Collismycin Analogs
1026 Chemistry & Biology 20, 1022–1032, August 22, 2013 ª2013 Elsevier Ltd All rights reserved
Table 1. Antiproliferative Assay of the Different Collismycin A
Analogs against a Panel of Tumor Cell Lines
Compound
Cell Line
NIH373
Fibroblast
A549
Lung
MDA-MD-231
Breast
HCT-116
Colon
Collismycin A 56.6 0.3 >100 0.6
Collismycin D 14 4.3 >100 4.8
Collismycin DN >100 >100 >100 >100
Collismycin DS >100 1.9 >100 1.7
Collismycin H >100 >100 >100 >100
Collismycin DH >100 90 100 >100
Collismycin DA >100 41.3 >100 6.6
Collismycin DC >100 >100 >100 >100
Collismycin H1 >100 63.5 >100 53
Collismycin H2 >100 >100 >100 >100
Collismycin H3 >100 84.7 >100 79.4
Collismycin H4 >100 >100 >100 >100
Collismycin H5 >100 >100 >100 >100
A fibroblast cell line was used as toxicity control; values represent IC50 in
micromoles.
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Generation of Collismycin Analogscompound was considered a good target to generate analogs
by enzymatic acylation. There are reports in the literature
describing acyltransferases with broad substrate specificity
(Xie et al., 2006). With this aim in mind, we chose a biocatalytic
acylation reaction, a greener alternative to conventional chem-
ical acylating reagents. We used lipase PS from Burkholderia
cepacia as biocatalyst and various esters (acetate, chloroace-
tate, butyrate, benzoate, and crotonate) as acyl donors. The
biotransformation with these acyl donors efficiently rendered
collismycin H analogs, carrying the corresponding acyl resi-
dues (Figure 3), namely acetyl (collismycin H1), chloroacetyl
(collismycin H2), butyryl (collismycin H3), crotonyl (collismycin
H4), and benzoyl (collismycin H5). The incorporations of the
corresponding acyl groups were verified with NMR and MS
of the product compounds (see Supplemental Experimental
Procedures).
Antiproliferative Activity of the Collismycin Analogs
Collismycin A and the 12 analogs were tested for in vitro inhibi-
tion of growth of three different tumor cell lines: A549 (lung),
HCT116 (colon), and MDA-MB-231 (breast) using as a control
for toxicity the NIH373 fibroblast cell line (Table 1). Collismycin
A showed half-maximal inhibitory concentration (IC50) values of
0.3, 0.6, and > 100 mM against the three cell lines, respectively.
Both collismycin A and the 12 analogs were poorly active against
the fibroblast cell line. Some of the compounds showed
IC50 values higher than or closer to 100 mM (collismycins H,
DH, DC, DN, H2, H3, H4, and H5), and collismycin H1 showed
IC50 values ten times higher than those of collismycin A. Three
analogs, collismycins D, DA, and DS, showed IC50 values close
to those of collismycin A.Figure 4. UPLC Analyses of Bioconversion Experiments
Cultures of CLM-N1 mutant (A, C, D, H, and I–K), CLM-G1G2 mutant (B), and CL
indicated in each panel. After 6 days of incubation at 30C, cultures were extracte
were extracted at 330 nm.
Chemistry & Biology 20, 1022–Neuroprotective Activity of the Collismycin Analogs
The neuroprotective action of collismycin A had been previously
reported (Martinez et al., 2007). We tested the collismycin ana-
logs as potential neuroprotectants using an in vivo zebrafish
model by determining induction of apoptosis in neural cells
and potential protection with these analogs. Three days postfer-
tilization (dpf), zebrafish larvae were incubated with all-trans ret-
inoic acid (RA) as a stress inducer in the presence or absence of
collismycin A and analogs. Then, apoptotic cells were observed
with fluorescence microscopy (Parng, 2005; Parng et al., 2007;
Selderslaghs et al., 2009). Control zebrafish larvae, with no RA
treatment, exhibited few or no apoptotic cells, while RA-treated
zebrafish exhibited a significant increase in apoptosis in the brain
region (Figure 5A). As a positive neuroprotectant control, lipoic
acid (LA) was used. Pretreatment of the larvae with LA reduced
apoptosis in approximately 61% at 1 mM. Zebrafish larvae
treated with 1 mM collismycin A were reduced the appearance
of apoptotic cells approximately 44% (Figure 5B). One of the
12 analogs (collismycin H) showed significantly improved neu-
roprotective activity compared to collismycin A, with a 60%
decrease in apoptosis induction (Figure 5B). Another four com-
pounds, collismycins D, DN, DS, and H1, also showed neuropro-
tective activity but to a similar or lower extent than collismycin A,
with 32%, 39%, 36%, and 44% apoptosis reductions, respec-
tively (Figure 5). The remaining six compounds did not show
any significant neuroprotective effect (see Supplemental Exper-
imental Procedures).
DISCUSSION
Collismycin A contains a two-pyridine ring system that is
biosynthesized from lysine involving NRPS and hybrid PKS-
NRPS multi-enzyme machineries. Two biosynthetic intermedi-
ates, collismycin SN and collismycin SC, were isolated after
insertional inactivation of two genes of the cluster (Garcia
et al., 2012). Further gene inactivation experiments, followed
by the isolation of the resulting mutant products, yielded seven
different collismycin analogs with minor chemical modifications
at C4, C5, or C6 positions of the substituted pyridine ring
(described in this manuscript). These results along with feeding
experiments of the mutant products to an early block mutant
allowed us to propose a pathway for the late steps of collismy-
cin A biosynthesis (Figure 6). In this pathway, some of the ana-
logs are proposed to be biosynthetic intermediates while others
are suggested to be ‘‘shunt products’’ generated by some
enzymes of the cluster but not acting in the proper order of
action. The action of amidohydrolase ClmAH would remove
the extra leucine residue added during the biosynthesis, gener-
ating collismycin C (isolated in this work), which contains a
carboxyl group at position 6. The enzyme pair ClmG1-ClmG2
constitutes of a carboxylic acid reductase, which would reduce
the carboxyl group to an aldehyde group. However, we have
been unable to isolate the aldehyde intermediate. Inactivation
of aminotransferase ClmAT, supposedly responsible for theM-D1 mutant (E–G) were fed with 50 mM of different collismycin A analogs as
d with ethyl acetate/formic acid 1% and analyzed with UPLC. Chromatograms
1032, August 22, 2013 ª2013 Elsevier Ltd All rights reserved 1027
Figure 5. Neuroprotective Action of the Collismycin Analogs
(A) Induction of apoptosis in a zebrafish model as visualized by fluorescence microscopy. The zebrafish larvae were treated with 10 mM RA alone as a stress
inducer (RA control) or in combination with 1 mM of the different collismycin analogs. As a positive neuroprotectant control, zebrafish were treated with
10 mM RA and 1 mM LA. See also Table S2.
(B) Effect of the different collismycin analogs on RA-induced apoptosis in zebrafish larvae. Apoptosis induced by RA in the presence or absence of different
collismycin analogs was determined with fluorescence microscopy and, after quantification, relative apoptosis was standardized using the level of apoptosis
generated by the RA treatment as 100%. One-way ANOVA and Dunnett’s t test were used to determine the significance. A p value less than 0.05 was
considered statistically significant. All analogs exhibited significant protection with p < 0.05. See also Table S1.
See also Figures S27–S29.
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Generation of Collismycin Analogstransamination of this aldehyde group, accumulated two com-
pounds containing a hydroxymethyl group in position 6 but it
did not accumulate the aldehyde intermediate. The sequential
reduction of oximes to alcohols mediated by alcohol dehydro-
genases has been reported, reactions in which only traces of
aldehydes could be detected (despite being the obvious
precursor; Ferreira-Silva et al., 2010). This suggests that the
reduction of the aldehyde is faster that the aldoxime reduction.
In our case, it is something similar; the reduction of the alde-
hyde is faster than the corresponding carboxylic acid reduction.
The two isolated compounds from CLM-AT mutant, collismycin
H and DH, only differing in the methylation state at position 4,
could be derived from the nonisolable aldehyde intermediate
by spontaneous reduction (and further methylation by ClmM2
in the case of collismycin H). The role of dehydrogenase
ClmD2 in the biosynthesis of collismycin A is therefore not
totally clear. Apparently, its participation is not absolutely
essential for collismycin A biosynthesis, because inactivation
of clmD2 does not prevent formation of collismycin A. However,
this mutant also accumulated collismycin H and collismycin DH,
which prompted us to propose that the action of ClmD2 could
be important for the producer organism, to recycle a spontane-
ously formed shunt product, collismycin DH, into the main
pathway, thereby diminishing the pathway shunt toward collis-
mycins DH and H.
The main pathway continues with aminotransferase ClmAT,
responsible for the transamination of the aldehyde group. So
far, we have not been able to isolate the resulting amine1028 Chemistry & Biology 20, 1022–1032, August 22, 2013 ª2013 Elanalog itself that should be accumulated by the CLM-M
mutant. Instead, this mutant accumulates an acetylated deriv-
ative (collismycin DA) of the expected amine compound,
which was shown to be a shunt product, because it is not con-
verted into collismycin A when fed to early block mutants.
The formation of collismycin DA is probably caused by an
undetermined acetyltransferase of the producer organism,
whose corresponding gene is located outside the clm gene
cluster.
Clearly, methyltransferase ClmM2 is responsible for the
O-methylation of the 4-OH group. Inactivation of clmM2 pro-
duced a mutant that accumulated three compounds, all of
them lacking the 4-methoxy group, thereby pinpointing ClmM20s
role for this O-methylation step. Two of the accumulated com-
pounds, collismycin DN and collismycin DS, also possess mod-
ifications at positions 5 and 6. None of them is a biosynthetic
intermediate, because they were not converted into collismycin
A by any of the mutants.
All seven collismycin analogs contain chemical modifications
in the substituted pyridine ring. By using a biocatalytic approach,
we also generated five additional analogs in which, using as
starting material collismycin H, we introduced different acyl moi-
eties (acetyl, chloroacetyl, butyryl, crotonyl, or benzoyl) at the
hydroxyl group of collismycin H.
Overall, 12 collismycin analogs were produced using these
two each other complementing pathway-bioengineering str-
ategies. All were initially tested for their cytotoxic activity
against a panel of three tumor cell lines. None of them showedsevier Ltd All rights reserved
Figure 6. Proposed Biosynthetic Pathway for Collismycin A Biosynthesis
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collismycin A, although three of the analogs (collismycins D,
DA, and DS) showed a cytotoxicity comparable to that of
collismycin A. Some conclusions can be drawn regarding
structure-function relationships. First, the presence of the
oxime moiety at the substituted ring seems to be important
for the cytotoxicity, although it can be replaced by a carbamoyl
moiety (as in collismycin DS), which has similar H-bonding
features. Second, the cytotoxic activity is not affected by the
methylation of the hydroxyl group at C4 of the substituted
ring, because analogs containing a 4-hydroxyl (e.g., collismy-
cins D and DS) or a 4-methoxy group (e.g., collismycin A) are
equally potent.
Zebrafish has been used as a model organism to determine
the toxicity of compounds, also for detecting environmental
hazards and for risk assessment (Chiu et al., 2008; Parng
2005; Tran et al., 2007). In addition, a zebrafish assay for in vivo
neuroprotective action has been developed (Parng et al., 2006).
We have used this model to assay the potential neuroprotective
activity of the collismycin analogs by determining apoptosis
induction caused by RA. One of the compounds tested,
collismycin H, showed enhanced neuroprotective activity when
compared to collismycin A. In addition, collismycin H showed
similar values of neuroprotection as those of the positive control
using lipoic acid and better neuroprotective values than collis-
mycin A. Interestingly, collismycin H showed very poor cytotoxic
activity. These two combined features are important for a com-
pound to be developed for potential clinical use: high efficiency
as neuroprotectant and very low cytotoxicity. Collismycin HChemistry & Biology 20, 1022–lacks the oxime group that seems to be important for the cyto-
toxic activity. On the other hand, the hydroxymethyl group at
C6 of collismycin H can be used as a handle for further minor
modifications (such as acetylation) without losing all neuropro-
tective activity, but it cannot be drastically modified by introduc-
tion of longer acyl groups, because some of the acylated
analogs, such as collismycins H2, H3, H4, and H5, lost the
neuroprotective ability.
Although the mechanism for collismycin cytotoxic and neuro-
protective activities is still unknown, it is possible to speculate
that they could be related to the ability to chelate metals, a
common property to the 2,20-bipyridyl family of compounds.
The 2,20-bipyridyls form complexes with several divalent metal
ions, especially copper and iron (Nakouti et al., 2012; Nocentini
and Barzi, 1996), and it is widely known that, because tumor cells
have higher requirements of iron due to their increased prolifer-
ation rate, treatment with iron chelators is an interesting
approach for cancer treatment (Kovacevic et al., 2011). Chela-
tors not only cause an arrest in DNA synthesis, they can also
affect the expression of key molecules involved in cell cycle
control and angiogenesis or directly generate oxidative stress
through the formation of redox iron complexes (Kovacevic
et al., 2011; Richardson, 2005). The affinity for iron of members
of the 2,20-bipyridyl family seems to be due to the pyridyl nitrogen
atoms and sometimes can be enhanced by the presence of a
third atom, such as the sulfur of the cytotoxic compound 2,20-
bipyridyl-6-carbothioamide (Antonini et al., 1981). Collismycin
A could behave as a tridentate ligand, too, with the third atom
being the nitrogen of the oxime. This could explain why, in the1032, August 22, 2013 ª2013 Elsevier Ltd All rights reserved 1029
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Generation of Collismycin Analogscollismycin analogs lacking the oxime moiety, the cytotoxic
activity is reduced, but the loss is less severe when a nitrogen
atom remains in that part of the molecule (i.e., collismycins DS
and DA). In the case of collismycin H, the replacement of the
oxime by a hydroxymethyl resulted in a drastic reduction of its
cytotoxic activity, while in contrast its neuroprotective activity
was improved.
Zebrafish neuroprotection assays against oxidative stress-
induced apoptosis have allowed the identification of neuropro-
tective compounds, such as free radical scavengers like
D-methionine, the steroid hormone cortisone, or iron chelators
like desferoxamine (Parng et al., 2006). These compounds, being
structurally quite diverse, probably exert their neuroprotective
role acting on different targets within the cell. There are com-
pounds that directly neutralize the formation of reactive oxygen
species, while others avoid their formation specifically by inacti-
vating enzymes involved in oxidative processes (Youdim et al.,
2004). In the case of collismycin A and its analogs, the fact that
the presence of the oxime seems to be essential for the cytotoxic
activity, whereas it does not affect the neuroprotective potential,
could indicate that these two activities are accomplished
through different mechanisms.
In summary, the combination of two different approaches
(insertional inactivation and biocatalysis) is a tool to increase
structural diversity in the 2,20-bipyridyl family of natural products.
Minor modifications in the collismycin A molecule contributed to
generate analogs possessing very low cytotoxic activity but
acquiring neuroprotective properties against oxidative stress
in zebrafish. This way, genetic engineering of the biosynthetic
pathway of an antitumor compound has rendered potential
analogs with potential as neuroprotectants.SIGNIFICANCE
Genetic engineering is a powerful tool for the generation
of derivatives of bioactive natural products. A number of
derivatives from different natural products synthesized by
microorganisms have been generated by combinatorial
biosynthesis. The use of this technology and its application
to the biosynthesis of the hybrid polyketide-nonribosomal
peptide collismycin A, a member of the 2,20-bipyridyl family,
together with a biocatalytic strategy allowed the generation
and isolation of 12 collismycin A derivatives. Some of these
compounds were accumulated bymutants in specific genes
of the cluster and the isolation and elucidation of their
chemical structures proposed a biosynthetic route to collis-
mycin A. Some of these derivatives showed potential neuro-
protective activity against oxidative stress in a zebrafish
model while in contrast they lack cytotoxic activity tested
against a panel of tumor cell lines. These two features are
expected for a compound to be potentially developed as
neuroprotectant.EXPERIMENTAL PROCEDURES
Bacterial Strains, Culture Conditions, and Vectors
Streptomyces sp. CS40, Streptomyces albus J1074, Escherichia coli DH10B
(Invitrogen), and E. coli ET12567 (pUB307; Kieser et al., 2000) were used in
this work. Plasmids pCR-Blunt (Invitrogen), pHZ1358 (Sun et al., 2009),1030 Chemistry & Biology 20, 1022–1032, August 22, 2013 ª2013 ElpEM4T (Mene´ndez et al., 2006), pUO9090 (Prado et al., 1999), and cosmid
cos1c3 (Garcia et al., 2012) were also used. All Streptomyces strains were
grown in specific media either for growth or production as detailed in the
Supplemental Experimental Procedures.
DNA Manipulation and Mutant Generation
DNA manipulation followed standard procedures (Sambrook et al., 1989).
Plasmid introduction into Streptomyces sp. CS40 or into S. albus was carried
by intergeneric conjugation using E. coli ET12567 (pUB307) as DNA donor
(Kieser et al., 2000). All collismycin nonproducing mutants were generated
by gene replacement. Two approximately 1.5 kb flanking regions for each
gene were obtained with PCR or enzymatic digestion and they were cloned
upstream and downstream from the apramycin resistance gene aac(3)IV
in pUO9090. Then the replacement cassette was subcloned into the
conjugative vector pHZ1358 and the resultant replacement plasmids were
introduced into Streptomyces sp. CS40 and thiostrepton-sensitive, apramy-
cin-resistant clones were selected. The occurrence of the gene replacement
was verified by Southern blot hybridization. Detailed description of the
generation of each mutant is provided in the Supplemental Experimental
Procedures.
Analysis and Purification of Compounds and Structural Elucidation
Cultures of the different strains were analyzed by ultra-performance liquid
chromatography (UPLC) and HPLC-MS for the presence of collismycin or
analogs. Ethyl acetate extracts of whole cultures were analyzed by reversed
phase chromatography, as detailed in the Supplemental Experimental
Procedures. Collismycin analogs were purified from liquid cultures in R5A
medium. Purification was carried out by a combination of solid-phase
extraction and preparative HPLC, as detailed in the Supplemental Experi-
mental Procedures. Structural elucidation of the 12 collismycin analogs
was determined with MS and NMR spectroscopy (see Supplemental Exper-
imental Procedures).
Bioconversion Experiments
Bioconversion assays were carried out in 24-square-deep well plates
(Enzyscreen). Streptomyces sp. mutant strains were grown as seed culture
in 3 ml of Tris-buffered saline. After 24 hr of growth in an orbital shaker
(30C/250 rpm), 0.1 ml of each culture was used to inoculate 2 ml of R5A sup-
plemented with 50 mMof collismycin analogs; after 6 days (30C/250 rpm) 2ml
of cultures were extracted with 2ml ethyl acetate/formic acid 1%and analyzed
with UPLC.
Generation of Analogs by Biocatalysis
Ester derivatives of collismycinHwere obtainedbymeans of a lipase-catalyzed
acylation. Lipase PS from Burkholderia cepacia (Amano) was chosen as the
biocatalyst, and vinyl acetate, vinyl chloroacetate, vinyl butyrate, vinyl benzo-
ate, and vinyl crotonate were tested as acyl donors. Reactions were assayed
at 30C and 250 rpmdissolving 5mg of collismycin H in 1ml of THF and adding
a 3 molar-fold of acylating agent and 10 wt % of enzyme. The lipase efficiently
catalyzed all the processes (conversion degree higher than 95% after 24 hr)
and, after purification by preparative HPLC, rendered collismycin H derivatives
with the corresponding acylated moieties.
Antiproliferative Activity
The cytotoxic activity of compounds was tested against three tumor cell lines:
A549 (lung), MDA-MB-231 (breast), and HCT116 (colon), using a fibroblast cell
line (NIH373) as control. Cells were incubated in 96-well plates (5,000 cells per
well) in 100 ml DMEM medium (Sigma) supplemented with 10% fetal bovine
serum (Biochrom) and 2 mM glutamine. After 24 hr, compounds (dissolved
in Dulbecco’s modified Eagle’s medium [DMEM]) were added at different
concentrations. As cell viability and as cell death controls, DMEM and 0.1%
SDS were added, respectively. After 24 hr of incubation, WST-8 reactive
(Cell Counting Kit-8, Sigma) was added and incubated for 2 hr at 37C and
then absorbance at 450 nm was determined in an EL3 800 microplate reader
(BioTek). Dose-response curves and IC50 values were obtained using Reader-
fit Online Software (Hitachi).sevier Ltd All rights reserved
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The potential of the collismycin analogs as neuroprotectants was tested in an
in vivo zebrafish model through the treatment of 3 dpf zebrafish larvae with
all-trans RA as the stress inducer alone or cotreatedwith the different collismy-
cin analogs. Apoptosis induction was then evaluated by acridinium chloride
staining and observation with fluorescence microscopy (see Supplemental
Experimental Procedures for details).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
29 figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2013.06.014.ACKNOWLEDGMENTS
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